Manfred Rüdiger

CEO

  Manfred Rüdiger has more than a decade of experience in the international biotech industry, where he served in various executive positions. He was previously CSO and acting CEO of Cardion AG (Düsseldorf, Germany), CEO of Igeneon AG (Vienna, Austria), COO of NASDAQ-listed Aphton Corporation (Philadelphia, US) and lastly CEO of t2cure GmbH (Frankfurt, Germany). He is currently also Venture Partner in the Munich Office of LSP, and is a member of the Board of Directors of 4SC AG. He has also served on the Boards of Vectron Therapeutics, and G2M AG and Aphton. Dr. Rüdiger received his PhD in biochemistry from the University of Tübingen, Germany and worked at the Max Planck Institute for Biophysical Chemistry, Göttingen, and at the Technical University of Braunschweig before he joined the industry. During that time he has authored numerous scientific papers and received several awards.